REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
23/01/2026
Voltar para busca
Dado oficial do USPTO
POTELLIGENT
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
POTELLIGENT
ST13
US500000078219523Classe
1, 5, 40
Pedido
78219523
Registro
3200292
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
55
Atualização mais recente
24/01/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 40
Data de depósito
27/02/2003
Data de registro
23/01/2007
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/03/2017
Última transação
24/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
1
Tipo de titular
03
Localização do titular
TOKYO, JP
Examinador
GRIFFIN, JAMES
Unidade examinadora
L30
Localização atual
TMEG LAW OFFICE 103
Titulares e representantes
Titulares
KYOWA KIRIN CO., LTD.
KYOWA HAKKO KIRIN CO., LTD.
Kyowa Hakko Kogyo Co., Ltd.
Representantes
Kaushal R. Odedra ODEDRA LAW OFFICE, PLLC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 40
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Cells that manufacture antibodiesfragments of antibodies or derivatives of antibodies for medical research; transfected cells that manufacture antibodiesfragments of antibodies or derivatives of antibodies for medical research
Classe 5
Cells that manufacture antibodiesfragments of antibodies or derivatives of antibodies for medical or clinical use; transfected cells that manufacture antibodiesfragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticalscentral nervous system depressantspreparations for ophthalmic useanti-histaminicscardiotonicsarrhythmia treating agentsdiureticshypotensorsprophylactic for the treatment of asthmaantitussives and expectorantsstomachics and digestivesantacidshormonespituitary hormones for the treatment of infertilitythyroid hormones for the treatment of hyperthyroidismanabolic hormones for the treatment of aplastic anemia and osteoporosiscorticosteroids for treatment of hypopituitarismcongenital adrenal hyperplasiarheumatoid arthritisrheumatic fevercrohn's diseasechronic active hepatitisestrogen and progesterone used as combined oral contraceptivesurinary antisepticsanalgesicsanti-itching agentscataplasms for the treatment of bruiseslumbago and stiff shoulderpharmaceutical preparations used to treat hair disordersanti-coagulantsenzyme preparations for control of malabsorption and diarrheaanti-cancer preparationsanti-sarcoma preparationsantibiotics and their preparations for the treatment of infectious diseasesantituberculotic agentsinfluenza vaccinesdiphtheria vaccinestetanus vaccinesgas gangrene vaccinesJapanese encephalitis vaccinesin vitro tetrodotoxines for medical useantiprotozoals for the treatment of trichomoniasis and dermatophytosisanthelmintics for the treatment of threadworm and toxoplasmaosisnaturally occurring drugs for treating peptic ulcerscharred drugs for treating peptic ulcersmoxa for treating peptic ulcersveterinary drugs for the treatment of distemper in dogsdistomatosis in dogscoccidium in chickensdysentery in pigsdrugs for arteriosclerosisoncostatic drugs for the treatment for cancermultienzyme digestants for in vivo useantifungal antibiotics for treating trichomoniasis and dermatophytosisantiparkinsonism drugsminor tranquilizersantianxiety agentsmedicinal preparations for the treatment of the central nervous systemthe respiratory tract and the cardiovascular systemanti-bacterial preparationsmucolytic preparationsmedicinal preparations for the treatment of peptic ulcersanti-inflammatory preparationsanalgesic preparationscephalosporincocarboxylase preparationsglutathione preparationspreparations for improving the metabolism and the peripheral circulationplasma substitutes and extracorporeal circulation flow improvement preparationsdiuretic and anti-hypertensive preparationspharmaceutical preparations for the treatment of insomnia and other sleep related diseases
Classe 40
Contract manufacturing service in the field of cells that manufacture antibodiesfragments of antibodiesderivatives of antibodies; contract manufacturing service in the field of transfected cells that manufacture antibodiesfragments of antibodiesderivatives of antibodies; contract extractingrefiningsynthesizingmanufacturing and preparing pharmaceuticalsagricultural chemicalschemicals
Publicações
Histórico de despachos e eventos da marca no USPTO.
55 publicações encontradas
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/09/2019
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
17/03/2017
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
17/03/2017
9G8P
REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8
17/03/2017
8PRT
REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED
17/03/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
17/03/2017
E89R
TEAS SECTION 8 & 9 RECEIVED
20/01/2017
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - MAILED
09/07/2013
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
09/07/2013
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/07/2013
E815
TEAS SECTION 8 & 15 RECEIVED
23/06/2013
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
19/11/2008
R.PR
REGISTERED-PRINCIPAL REGISTER
23/01/2007
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
05/12/2006
IUCN
NOTICE OF ALLOWANCE CANCELLED
30/11/2006
FAXX
FAX RECEIVED
30/11/2006
NOAM
NOA MAILED - SOU REQUIRED FROM APPLICANT
17/10/2006
PUBO
PUBLISHED FOR OPPOSITION
25/07/2006
NPUB
NOTICE OF PUBLICATION
05/07/2006
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/06/2006
ALIE
ASSIGNED TO LIE
26/05/2006
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
24/05/2006
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/05/2006
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/05/2006
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/05/2006
CNCF
CONTINUATION OF FINAL REFUSAL MAILED
28/04/2006
CNCF
ACTION CONTINUING A FINAL - COMPLETED
27/04/2006
CNEA
EXAMINERS AMENDMENT MAILED
27/04/2006
XAEC
EXAMINER'S AMENDMENT ENTERED
27/04/2006
CNEA
EXAMINERS AMENDMENT -WRITTEN
27/04/2006
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
21/03/2006
CNFR
FINAL REFUSAL MAILED
06/03/2006
CNFR
FINAL REFUSAL WRITTEN
03/03/2006
ACEC
AMENDMENT FROM APPLICANT ENTERED
09/02/2006
PAPER RECEIVED
07/02/2006
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/02/2006
PAPER RECEIVED
03/02/2006
CRML
CORRESPONDENCE MAILED
18/10/2005
CNRT
NON-FINAL ACTION WRITTEN
18/10/2005
ACEC
AMENDMENT FROM APPLICANT ENTERED
26/09/2005
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/09/2005
PAPER RECEIVED
19/09/2005
CNSL
LETTER OF SUSPENSION MAILED
13/05/2005
CNSL
SUSPENSION LETTER WRITTEN
12/05/2005
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/05/2005
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/05/2005
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/05/2005
CNSI
INQUIRY AS TO SUSPENSION MAILED
22/11/2004
CNSI
SUSPENSION INQUIRY WRITTEN
19/11/2004
CNSL
LETTER OF SUSPENSION MAILED
26/03/2004
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/02/2004
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/02/2004
CNRT
NON-FINAL ACTION MAILED
19/08/2003
DOCK
ASSIGNED TO EXAMINER
14/08/2003
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace POTELLIGENT ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.